Reuters logo
BRIEF-Amgen says FDA grants full approval for Blincyto to treat relapsed or refractory b-cell precursor acute lymphoblastic leukemia
July 11, 2017 / 11:58 PM / 2 months ago

BRIEF-Amgen says FDA grants full approval for Blincyto to treat relapsed or refractory b-cell precursor acute lymphoblastic leukemia

July 11 (Reuters) - Amgen Inc

* FDA grants full approval for blincyto® (blinatumomab) to treat relapsed or refractory b-cell precursor acute lymphoblastic leukemia in adults and children

* Amgen Inc - u.s. Fda approved supplemental biologics license application for blincytoto include overall survival data from phase 3 tower study

* Approval converts blincyto’s accelerated approval to a full approval Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below